APPLICATION OF THE CYP3A4 SELECTIVE MECHANISM-BASED INACTIVATOR CYP3CIDE TO DELINEATE CYP3A4 AND CYP3A5 CONTRIBUTIONS TO THE METABOLISM OF CYP3A CLEARED DRUGS

被引：0
|
作者：
Tseng, Elaine [1 ]
Walsky, Robert L. [2 ]
Luzietti, Rick [2 ]
Harris, Jennifer [2 ]
Kosa, Rachel E. [1 ]
Zientek, Michael A. [3 ]
Goosen, Theunis C. [1 ]
Obach, R. Scott [1 ]
机构：
[1] Pfizer Global Res & Dev, Groton, CT USA
[2] AstraZeneca, Waltham, MA USA
[3] Pfizer Global Res & Dev, La Jolla, CA USA
来源：
DRUG METABOLISM REVIEWS | 2014年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [31] Differences in CYP3A4*1G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations
    Du, Jing
    Yu, Lan
    Wang, Lei
    Zhang, Aiping
    Shi, Yongyong
    Li, Xingwang
    Xing, Qinghe
    He, Lin
    Shu, Anli
    Xu, Lingyun
    Xu, Mingsheng
    Feng, Guoyin
    CLINICA CHIMICA ACTA, 2007, 383 (1-2) : 172 - 174
  • [32] Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans
    Santos, A
    Zanetta, S
    Cresteil, T
    Deroussent, A
    Pein, F
    Raymond, E
    Vernillet, L
    Risse, ML
    Boige, V
    Gouyette, A
    Vassal, G
    CLINICAL CANCER RESEARCH, 2000, 6 (05) : 2012 - 2020
  • [33] The contribution of CYP3a4 and CYP3A5 on the metabolism of sildenafil, vardenafil, and udenafil.
    Ku, H.
    Bae, S.
    Seo, K.
    Ahn, H.
    Bae, S.
    Shon, J.
    Liu, K.
    Shin, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S49 - S49
  • [34] In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans
    Hirota, N
    Ito, K
    Iwatsubo, T
    Green, CE
    Tyson, CA
    Shimada, N
    Suzuki, H
    Sugiyama, Y
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2001, 22 (02) : 53 - 71
  • [35] Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients
    Willrich, Maria Alice V.
    Rodrigues, Alice C.
    Cerda, Alvaro
    Genvigir, Fabiana D. V.
    Arazi, Simone S.
    Dorea, Egidio L.
    Bernik, Marcia M. S.
    Bertolami, Marcelo C.
    Faludi, Andre
    Largura, Alvaro
    Baudhuin, Linnea M.
    Bryant, Sandra C.
    Hirata, Mario Hiroyuki
    Crespo Hirata, Rosario Dominguez
    CLINICA CHIMICA ACTA, 2013, 421 : 157 - 163
  • [36] Mechanism-based inhibition of CYP3A4 and CYP3A5 by troleandomycin, 6′, 7 dihydroxybergamottin, diltiazem, and verapamil
    Patki, KC
    von Moltke, LL
    Greenblatt, DJ
    DRUG METABOLISM REVIEWS, 2003, 35 : 173 - 173
  • [37] Genetic Variants of CYP3A4 and CYP3A5 in Cynomolgus and Rhesus Macaques
    Uno, Yasuhiro
    Matsushita, Akinori
    Osada, Naoki
    Uehara, Shotaro
    Kohara, Sakae
    Nagata, Ryoichi
    Fukuzaki, Koichiro
    Utoh, Masahiro
    Murayama, Norie
    Yamazaki, Hiroshi
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (02) : 209 - 214
  • [38] Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5
    Soars, M. G.
    Grime, K.
    Riley, R. J.
    XENOBIOTICA, 2006, 36 (04) : 287 - 299
  • [39] The evaluation of CYP3A4 and CYP3A5 genetic profiles in Turkish population
    Arici, Merve
    Ozhan, Gul
    ISTANBUL JOURNAL OF PHARMACY, 2016, 46 (01): : 15 - 22
  • [40] CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer
    Plummer, SJ
    Conti, DV
    Paris, PL
    Curran, AP
    Casey, G
    Witte, JS
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (09) : 928 - 932
12345